Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.12.2013 | comment | Ausgabe 4/2013

memo - Magazine of European Medical Oncology 4/2013

ASCO 2013—new concepts and the path to individualized therapy

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 4/2013
Autor:
Univ. Prof. Dr. Heinz Zwierzina

Abstract

At American Society of Clinical Oncology’s 2013 meeting, the clinical development of innovative drugs targeting the immune system and progress in biomarker research represented some of the highlights. During recent years, immunomodulatory agents have become a very active field in clinical cancer research. After the successful development of the anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) antibody ipilimumab in melanoma, the “programmed cell death protein 1” pathway is expected to become a cornerstone in several tumor types. One key challenge for anticancer treatment, in general, is the definition of biomarkers and the further individualization of therapy. Progress in molecular phenotyping and in serum proteomics as predictive markers was reported.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2013

memo - Magazine of European Medical Oncology 4/2013 Zur Ausgabe